结核与肺部疾病杂志 ›› 2023, Vol. 4 ›› Issue (4): 261-271.doi: 10.19983/j.issn.2096-8493.20230073

• 专论 •    下一篇

结核病比较免疫学,应对全球结核病挑战的技术关键

朱国峰1(), 余卫业2(), 汪源3(), 刘晓清4(), 高谦5(), 李亮6(), 卢洪洲1()   

  1. 1深圳市第三人民医院/国家感染性疾病临床医学研究中心,深圳 518112
    2深圳市卫生经济协会,深圳 518020
    3国家科学技术部重大科技专项司,北京 100862
    4中国医学科学院北京协和医学院/北京协和医院内科学系感染内科/疑难重症及罕见病国家重点实验室,北京 100730
    5复旦大学基础医学院,教育部/卫健委/医科院医学分子病毒学重点实验室,上海 200032
    6首都医科大学附属北京胸科医院,北京 101149
  • 收稿日期:2023-06-16 出版日期:2023-08-20 发布日期:2023-08-15
  • 通信作者: 朱国峰, Email: zhugf2014@126.com;余卫业, Email: ywy2202@126.com;汪源, Email: 41824660@qq.com;刘晓清, Email: liuxq@pumch.cn;高谦, Email: qiangao@fudan.edu.cn;李亮, Email: liliang69@vip.sina.com;卢洪洲, Email: luhongzhou@fudan.edu.cn

Systematic immunology of tuberculosis,a critical step in the global war against tuberculosis disease

Zhu Guofeng1(), Yu Weiye2(), Wang Yuan3(), Liu Xiaoqing4(), Gao Qian5(), Li Liang6(), Lu Hongzhou1()   

  1. 1National Clinical Research Center for Infectious Diseases/The Third People’s Hospital of Shenzhen, Shenzhen 518112, China
    2Shenzhen Municipal Health Economics Association, Shenzhen 518020,China
    3Department of National Science and Technology Major Project,Ministry of Science and Technology,Beijing 100862,China
    4Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
    5Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Shanghai Medical College, Fudan University, Shanghai 200032, China
    6Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
  • Received:2023-06-16 Online:2023-08-20 Published:2023-08-15
  • Contact: Zhu Guofeng, Email: zhugf2014@126.com; Yu Weiye, Email: ywy2202@126.com; Wang Yuan, Email: 41824660@qq.com; Liu Xiaoqing, Email: liuxq@pumch.cn; Gao Qian, Email: qiangao@fudan.edu.cn; Li Liang, Email: liliang69@vip.sina.com; Lu Hongzhou, Email: luhongzhou@fudan.edu.cn

摘要:

2013年MVA85A临床实验的失败,标志着全球结核病疫苗和药物研究进入一个全新的历史时代。以结核病比较免疫学竞争为核心的全球结核病防治创新理论研究和新型技术产品研发,是决定未来每个国家在全球结核病防治领域话语权和影响力的关键。这其中的关键,就是能否牢牢把握结核病比较免疫学的核心技术竞争实力,举得起结核病比较免疫学新技术时代的高科技大旗,并籍此抓实结核病临床负担向科研资源转型的机遇,抓实中外传染病防控政策交流关口转型的历史机遇。

关键词: 结核, 免疫学技术, 疾病模型,动物, 疫苗, 比较免疫学

Abstract:

A new era of novel vaccine and drug development against tuberculosis disease arrived with the failed clinical trial of MVA85A published in 2013. The breakthrough of systematic immunology of tuberculosis, which is the most critical challenge in developing novel technologies and products to end tuberculosis, is leading the reconstruction of the feature and position of strength of all countries in the ongoing struggle of global tuberculosis control.

Key words: Tuberculosis, Immunologic techniques, Disease models, animal, Vaccines, Systematic immunology

中图分类号: